Acute Lymphoblastic Leukemia

Previously Untreated

- Age 18-39
  - SWOGACCL1931
    - Phase III Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents & Young Adults Receiving Acute Lymphoblastic Leukemia Therapy
      - PI: Liedtke
      - Sponsor: COG
  - SWOGA041501
    - Phase III Inotuzumab Ozogamicin (Anti-CD22 Mab) vs Frontline Tx in Newly Diagnosed Precursor B-Cell ALL
      - PI: Liedtke
      - Sponsor: SWOG
  - SWOGA042001
    - Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy vs Standard Chemotherapy in Older Adults with Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
      - PI: Liedtke
      - Sponsor: SWOG

- Age 50+
  - HEM0060
    - COVALENT-101: Phase I First-In-Human Dose-Escalation & Dose-Expansion Study of BMF-218 (Oral, Covalent, Menin Inhibitor) in Acute Leukemia (AL) Diffuse Large B-cell Lymphoma (DLBCL) Multiple Myeloma (MM) & Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
      - PI: Coute
      - Sponsor: Novartis

Relapsed / Refractory

CD19-Positive

- CCT5052
  - Phase I Open Label Dose Escalation Study of YT8323 in CLL/SL and DLBCL
    - PI: Coute
    - Sponsor: Novartis